Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET

Usefulness of 99mTc-pertechnetate single-photon emission computed tomography in remnant mass estimation of postsurgical patients of differentiated thyroid cancer during internal dosimetry

“…Further, ultrasound facility is not available in a nuclear medicine setup and at times it becomes difficult to avail the facility to the convenience of the patient. Planar images, obtained after I-131 administration, by rectilinear scanner or camera fitted with medium-energy collimator have also been used for mass estimation [2,19]. However, these methods require using empirical formulas and geometric assumption regarding the third dimension, that is, the thickness of the tissue.…”

Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy

“…Early severe haematological toxicity is unusual but late morbidity such as salivary gland dysfunction appears to be a common problem. For the future, methods of increasing tumour dose should be developed including higher administered activities (with peripheral blood stem cell support if necessary), increased tumour uptake using recombinant TSH and techniques to delay transit of the radioiodine through the tumour [23][24][25][26][27].…”

Dosimetry: Does it Really Matter?

“…The result of this is that it is a well-known fact that for some common radiopharmaceutical therapies, there is a wide range of internally absorbed doses delivered to various organs. For example, for the most common therapeutic procedure in nuclear medicine practice worldwide, I-131 thyroidal ablation, absorbed doses can range from 7-3500 Gy in one report [1] and 1.2 to 540 Gy in another. [2] Put in a very crude way, this is akin to giving patients anything from 35-17,500 mg of paracetamol per administration for fever!…”